PharmaEssentia Corp.
35.60
USD
-0.60
(-1.66%)
ISIN
US7169721047
CUSIP
716972104
Return %
Stock
S&P 500
1Y
136.62
14.20
3Y
312.10
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Kuo Chung Lin
- Full Time Employees
- 342
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 3, Park Street Taipei TPE Taiwan 115
- IPO Date
- Mar 11, 2014
- Website
- pharmaessentia.com
- Similar Companies
- Business
- PharmaEssentia Corporation develops, manufactures, and commercializes biopharmaceutical products primarily focused on hematology and oncology, with an emphasis on novel therapies for myeloproliferative neoplasms (MPNs) such as polycythemia vera (PV), essential thrombocythemia (ET), myeloid fibrosis (MF), and chronic myeloid leukemia (CML). Its core products include BESREMi (ropeginterferon alfa-2b), a next-generation long-acting interferon approved for the treatment of PV in multiple regions including the US, EU, Japan, and Taiwan. The company’s product portfolio also extends to investigational drugs targeting hematologic malignancies and liver diseases like chronic hepatitis C. PharmaEssentia operates globally with subsidiaries and licensing partnerships, serving markets across North America, Europe, Asia, and Latin America. The company was founded in 2000 and is headquartered in Taiwan. In recent major developments, PharmaEssentia entered an exclusive licensing agreement in 2024 with FORUS Therapeutics for the registration and commercialization of BESREMi in Canada, which includes milestone payments up to $107 million and royalty arrangements, marking a strategic expansion in North America. The company reports strong revenue growth driven by its flagship drug BESREMi, with a 60%+ increase in 2025 despite aggressive R&D investment to advance its clinical pipeline. PharmaEssentia also completed a global Phase III clinical trial for Ropeg in ET, underscoring its commitment to expanding indications for its core therapeutic. Operationally, it has enhanced manufacturing capabilities with a cGMP-certified facility in Taichung, Taiwan, and continues to cultivate partnerships to broaden its geographic reach and product availability. PharmaEssentia’s strategic focus lies in innovative biologics for hematology and oncology with progressive expansion through licensing, partnerships, and pipeline development, aiming to provide patients worldwide with improved therapeutic options. Its business model combines in-house drug development with global commercialization alliances to maximize market penetration and patient access. The company’s strong R&D emphasis fuels long-term growth prospects, supported by regulatory approvals across key international markets. PharmaEssentia is positioned as a specialized biopharmaceutical innovator addressing rare and complex diseases with a growing global footprint and a pipeline advancing towards new indications and geographic regions.